Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Standing Risk Factors

  • Going Concern Doubt (unchanged) — The company continues to disclose substantial doubt about its ability to continue as a going concern, with cash of only $1.8 million as of March 31, 2026.
NASDAQ: TPST Tempest Therapeutics, Inc. 10-Q

Cash and cash equivalents dropped 76.6% to $1.8M as of March 31, 2026, and the company continues to disclose substantial doubt about its ability to continue as a going concern.

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~1 min read

Key Changes

  • high

    Research and development expense excluding acquired in-process costs fell 98.5% to $114,000, while general and administrative expense rose 63.9% to $5.4M.

  • high

    The company issued 9.4M shares during the quarter, increasing shares outstanding to 14.3M shares, primarily through an asset acquisition and a financing facility with Factor.

  • medium

    Operating cash outflow improved slightly to $7.6M from $8.0M a year earlier, while financing activities provided $1.7M.

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade TPST commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify